Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CHKA | P35790 | 4/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44501 | 0.93 | ALDH1A1 (0.67) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| Hydrochloric Acid SCHEMBL2870922 | 0.90 | ALDH1A1 (0.64) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL13821789 | 0.86 | ALDH1A1 (0.81) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL10062463 | 0.85 | HRH3 (0.46) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL919282 | 0.85 | HRH3 (0.46) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL2776957 | 0.82 | TP53 (0.56) | ALDH1A1TSHRMAPK1TDP1SMN1; SMN2 | |
| SCHEMBL1702558 | 0.82 | TP53 (0.56) | ALDH1A1TSHRMAPK1TDP1SMN1; SMN2 | |
| SCHEMBL124209 | 0.82 | ALDH1A1 (0.79) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| SCHEMBL11547412 | 0.82 | ALDH1A1 (0.79) | ALDH1A1TSHRCYP3A4MAPK1TDP1 | |
| Methane SCHEMBL2520492 | 0.81 | ALDH1A1 (0.81) | ALDH1A1TSHRCYP3A4MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-05-26 | — | — | US | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| EP-3309618-A1 | POLYCARBONATE CONTAINING PHOTOCONDUCTORS | Xerox Corporation (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2017049172-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-8791104-B2 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791104-B2 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-12 | — | — | US | disclosed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090253686-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090253686-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-10-08 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053193-A2 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053725-A2 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | ALDH1A1 2869/4885TSHR 4456/4885CYP3A4 2947/4885 |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | ALDH1A1 1177/4885TSHR 980/4885CYP3A4 800/4885 |
| US-20220162229-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | ALDH1A1 2869/4885TSHR 4456/4885CYP3A4 2947/4885 |
| US-20090275099-A1 | Methods and compositions for treating diseases and conditions associated with mitochondrial function | ATP5F1A, ATP5MF, MT-ATP6 | ALDH1A1 1703/4885TSHR 4691/4885CYP3A4 3533/4885 |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | GABRA5, GABRA3, GABRA6 | ALDH1A1 2225/4885TSHR 1574/4885CYP3A4 21/4885 |
| US-20090253686-A1 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | GABRA5, GABRA3, GABRA6 | ALDH1A1 2225/4885TSHR 1574/4885CYP3A4 21/4885 |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | BAD, GABRA5, GABRB1 | ALDH1A1 1177/4885TSHR 980/4885CYP3A4 800/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | ALDH1A1 1113/4885TSHR 4539/4885CYP3A4 1399/4885 |
| US-20120088757-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | ALDH1A1 1177/4885TSHR 980/4885CYP3A4 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.